On August 20, Novartis AG rose 3.11% in regular trading, trading at 159.52 USD/share, with turnover of $229 million.

On the news front, Novartis recently won a UK court challenge to its Entresto patent. The court ruled that both the patent and supplementary protection certificate remain valid, and that Accord Healthcare's planned generic version would constitute infringement. Entresto accounts for approximately 10% of Novartis's total sales, with the supplementary protection certificate effective through 2028, reinforcing the company's mid-term revenue expectations.

Additionally, Novartis's previously reported Q2 results significantly beat consensus, with adjusted EPS of $2.41 versus the $2.13 estimate, representing a 13% beat, while net sales of $14.41 billion also exceeded the $14.04 billion forecast. The strong performance was driven by innovative drug portfolio growth offsetting generic competition headwinds.

Within the Pharmacy sector, broader strength was evident. Among peers, Merck rose 11.67%, Eli Lilly gained 3.68%, Pfizer advanced 3.39%, Bristol-Myers Squibb added 2.0%, and Johnson & Johnson increased 0.81%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)